| Literature DB >> 24929563 |
Selina K Tour, Kim S Thomas1, Dawn-Marie Walker, Paul Leighton, Adrian Sw Yong, Jonathan M Batchelor.
Abstract
BACKGROUND: Vitiligo is a chronic depigmenting skin disorder which affects around 0.5-1% of the world's population. The outcome measures used most commonly in trials to judge treatment success focus on repigmentation. Patient-reported outcome measures of treatment success are rarely used, although recommendations have been made for their inclusion in vitiligo trials. This study aimed to evaluate the face validity of a new patient-reported outcome measure of treatment response, for use in future trials and clinical practice.Entities:
Mesh:
Year: 2014 PMID: 24929563 PMCID: PMC4075774 DOI: 10.1186/1471-5945-14-10
Source DB: PubMed Journal: BMC Dermatol ISSN: 1471-5945
Figure 1Participant flow diagram. Flow diagram to show participant numbers lost and included throughout the study process.
Demographic/other characteristics of survey respondents
| 149 (90.3) | 12 (100) | |
| 14 (8.5) | 0 (0) | |
| 13(92.9) | ||
| 1 (7.1) | ||
| 2 (1.2) | 0 (0) | |
| 0 (0) | 0 (0) | |
| <5 years | 1 (0.6) | 0 (0) |
| 5-16 years | 10 (6.1) | 1 (8.3) |
| 17-30 years | 17 (10.3) | 2 (16.7) |
| 31-45 years | 43 (26) | 3 (25) |
| 46-65 years | 55 (33.3) | 3 (25) |
| > 65years | 29 (17.6) | 3 (25) |
| Unknown | 10 (6.1) | 0 (0) |
| White British | 117 (70.9) | 9 (75) |
| White Irish | 1 (0.6) | 0 (0) |
| Other White Background | 15 (9.1) | 0 (0) |
| Any Other Mixed Background | 1 (0.6) | 0 (0) |
| Indian/British Indian | 9 (5.5) | 1 (8.3) |
| Pakistani/British Pakistani | 1 (0.6) | 0 (0) |
| Bangladeshi/British Bangladeshi | 2 (1.2) | 1 (8.3) |
| Caribbean/British Caribbean | 1 (0.6) | 1 (8.3) |
| African/British African | 1 (0.6) | 0 (0) |
| Other | 7 (4.2) | 0 (0) |
| Unknown | 10 (6.1) | 0 (0) |
| UK | 135 (81.8) | 11 (91.7) |
| USA | 12 (7.3) | 1 (8.3) |
| Europe (excluding UK) | 3 (1.8) | 0 (0) |
| Australia | 1 (0.6) | 0 (0) |
| Asia | 1 (0.6) | 0 (0) |
| Dual – UK and Other | 2 (1.2) | 0 (0) |
| Unknown | 11 (6.7) | 0 (0) |
| 6-12 months | 3 (1.9) | 0 (0) |
| 1-2 years | 3 (1.9) | 0 (0) |
| 2-5 years | 12 (7.7) | 2 (16.7) |
| 5-10 years | 26 (16.8) | 1 (8.3) |
| > 10 years | 111 (71.6) | 9 (75) |
| 0-10% | 37 (23.3) | 1 (8.3) |
| 10-25% | 49 (30.8) | 4 (33.3) |
| 25-50% | 33 (20.8) | 5 (41.7) |
| 50-80% | 24 (15.1) | 2 (16.7) |
| >80% | 16 (10.1) | 0 (0) |
| Unknown | 6 (3.6) | 0 (0) |
| Face/Neck | 129 (78.2) | 10 (83.3) |
| Body | 110 (66.7) | 7 (58.3) |
| Arms | 113 (68.5) | 8 (66.7) |
| Legs | 109 (66.1) | 8 (66.7) |
| Hands | 127 (77) | 10 (83.3) |
| Feet | 113 (68.5) | 9 (75) |
| I’d rather not say | 2 (1.2) | 0 (0) |
| Other (responses included: under arms, genitalia and hair) | 35 (21.2) | 2 (16.7) |
| No treatment | 57 (34.5) | 2 (16.7) |
| Topical corticosteroid | 41 (24.8) | 3 (25) |
| Protopic (Tacrolimus) | 46 (27.9) | 6 (50) |
| Elidel (Pimecrolimus) | 6 (3.6) | 0 (0) |
| Vitamin D derived cream or ointment (e.g. calcipotriol) | 5 (3) | 2 (16.7) |
| UVB | 33 (20) | 5 (41.7) |
| PUVA | 20 (12.1) | 2 (16.7) |
| Not Sure | 1 (0.6) | 0 (0) |
| Other (Responses included diet changes and alternative therapies) | 28 (17) | 3 (25) |
‘When thinking about repigmentation of vitiligo after treatment, what does a “cosmetically acceptable result” mean to you?’ (Themes in descending order of popularity)
| Blends well with skin | 45 | 19% |
| Less noticeable | 35 | 14.8% |
| Skin back to normal | 31 | 13.1% |
| Reduction in white patches | 29 | 12.2% |
| Confident/Comfortable | 25 | 10.5% |
| Repigment visible sites | 19 | 8% |
| Any Improvement | 17 | 7.2% |
| Mostly repigmented | 14 | 5.9% |
| Cosmetics | 9 | 3.8% |
| Unaffected by tanning | 5 | 2.1% |
| Means nothing | 4 | 1.7% |
| Lasting repigmentation | 3 | 1.3% |
| Completely depigmented | 1 | 0.4% |
Popularity of Words/Phrases to describe treatment results for vitiligo
| Good colour match between treated vitiligo patches and normal skin | 72 | 17% |
| Skin is back to normal | 66 | 15.6% |
| Feel better about appearance of skin | 58 | 13.7% |
| Reduction in area of skin affected by vitiligo | 48 | 11.3% |
| Even pattern of repigmentation | 43 | 10.2% |
| Cosmetically acceptable result | 26 | 6.1% |
| Satisfied with result | 23 | 5.4% |
| Worth continuing with treatment | 21 | 5% |
| Other | 18 | 4.3% |
| Worthwhile result | 17 | 4% |
| Result of treatment is acceptable | 9 | 2.1% |
Themes emerging from “other suggested questions”
| Psychological | 36 | 34.6% |
| Treatment details | 19 | 18.3% |
| Improvement duration | 14 | 13.5% |
| Was the treatment worth the results | 8 | 7.7% |
| Adverse effects | 6 | 5.8% |
| Satisfaction | 6 | 5.8% |
| Back to normal | 4 | 3.8% |
| Has colour returned | 3 | 2.9% |
| Reduction in white patches | 3 | 2.9% |
| Sun protection | 2 | 1.9% |
| Would they do it again | 2 | 1.9% |
| Make it simple | 1 | 1% |
Worthwhile treatment response and minimum level of response acceptable for after 9 months
| A (20) | 2 (1.3) | 8 (5.1) |
| B (30) | 0 (1.3) | 8 (10.2) |
| C (40) | 3 (3.2) | 7 (14.7) |
| D (50) | 7 (7.6) | 17 (25.6) |
| E (60) | 8 (12.1) | 16 (35.9) |
| F (70) | 12 (19.8) | 26 (52.6) |
| G (80) | 18 (31.6) | 43 (80.2) |
| H (95) | 57 (77.7) | 22 (94.3) |
| I (100) | 51(100) | 9 (100) |
Wording of response options
| Worse than before (1) | More noticeable (1) |
| About the same (2) | As noticeable (2) |
| Slightly less noticeable (3) | Slightly less noticeable (3) |
| A lot less noticeable (4) | A lot less noticeable (4) |
| Hardly noticeable (5) | No longer noticeable (5) |
Figure 2A set of ‘before’ and ‘after’ images showing hyperpigmentation used in the online discussion groups. A set of ‘before’ and ‘after’ images showing hyperpigmentation used in the online discussion groups. This set of images consent was gained from the individual seen in Figure 2 for use of their images in research publications as well as was obtained from images held at the Centre of Evidence Based Dermatology of before and after treatment. Full future studies.